# national reimbursement

Recordati’s China Exit Leaves Cushing’s Patients Stranded and Exposes Fragile Market for Rare‑Disease Drugs

Recordati’s Chinese subsidiary has filed to deregister, ending supply of osilodrostat — the only oral drug for Cushing’s syndrome on the Chinese market — less than a year after its commercial launch. The withdrawal highlights structural problems in China’s rare‑disease market: high prices, thin sales, uncertain reimbursement and weak incentives for suppliers, all of which risk interrupting care for vulnerable patients.